期刊文献+

冠心病患者检测血清半胱氨酸蛋白酶抑制剂C的意义

下载PDF
导出
摘要 目的探讨血清半胱氨酸蛋白酶抑制剂C与冠心病发生发展的关系。方法血清半胱氨酸蛋白酶抑制剂C测定采用透射比浊法,分别测定冠心病组和正常对照组血清半胱氨酸蛋白酶抑制剂C水平。结果冠心病组血清半胱氨酸蛋白酶抑制剂C明显高于对照组,且随着冠心病病情的加重血清半胱氨酸蛋白酶抑制剂C水平有逐步升高趋势。结论血清半胱氨酸蛋白酶抑制剂C水平与冠心病发生发展相关。
出处 《浙江实用医学》 2007年第4期236-237,共2页 Zhejiang Practical Medicine
  • 相关文献

参考文献15

  • 1吴光哲,张必利,郑兴,秦永文.慢性肾脏病与冠心病相关性的临床研究[J].心血管康复医学杂志,2006,15(5):447-450. 被引量:17
  • 2Anavekar N S,Mc Murray J J,Velazquez E J,et al.Relation between renal dysfunction and caediovascular outcomes after myocardial infarction.N Engl J Med.2004,351:1285
  • 3Jung K,Jung M.Cystatin C:a promising marker of glomerular filtration rate to replace creatitine,Nephron,1995,70:370
  • 4Newman D J,Thakkar H,Edwards R G,et al.Serum cystatin C measured by automated immunoassay:a more sensistive marker of changes in GFR than serum creatitine.Kidney Int,1995,47:312
  • 5J H IX,M G Shlipak,G M Chertow,et al.Association of Cystatin C with Mortality,Cardiovascular Events,and Incident Heart Failure Among Persons With Coronary Heart Disease:Date From the Heart and Soul Study.Circulation,Janyary 16,2007;115(2):173
  • 6Laterza O F,Price C P,Scott M G.Cystatin C:an improved estimater of glomerular filtration rate?Clin Chem.2002,48:699
  • 7黄萍.评估肾脏功能的一种更敏感指标—胱蛋白C[J].国外医学(泌尿系统分册),2001,21(5):228-229. 被引量:13
  • 8Jernberg T,Lindahl B,James S,et al.Cystatin C:a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome.Circulation,2004,110:2342
  • 9Pinkan T,Hilgers K F,Veelken R,et al.How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease.J Am Soc Nephrol,2004,15(3):517
  • 10Fliser D,Kielstein J T,Bode-Boger S M,et al.Asymmetric dimethylarginine(ADMA):a cardiovascular risk factor in patients with renal disease.Kidney Int,2003,63(Suppl 84):S37

二级参考文献50

  • 1杨小兵,侯凡凡,武强,周华,刘郑荣,杨燕,张训.慢性肾脏病患者晚期氧化蛋白产物血症及其与动脉粥样硬化的关系[J].中华内科杂志,2005,44(5):342-346. 被引量:41
  • 2Foley RN, Parfrey PS, Sarnak MJ.Clinical epidemiology of cardiovascular disease in chronic renal disease.Am J Kidney Dis,1998,32(5 Suppl 3):S112-S119.
  • 3Witko-Sarsat V, Friedlander M, Capeillere-Blandin C,et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int, 1996,49:1304-1313.
  • 4Witko-Sarsat V, Friedlander M, Nguyen Khoa T,et al.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol,1998,161:2524-2532.
  • 5Stein G, Busch M, Muller A, et al.Are advanced glycation end products cardiovascular risk factors in patients with CRF?Am J Kidney Dis,2003,41(3 Suppl 1):S52-S56.
  • 6Craven TE, Ryu JE, Espeland MA,et al.Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study.Circulation,1990,82:1230-1242.
  • 7Stenvinkel P, Heimburger O, Paultre F,et al.Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.Kidney Int,1999,55:1899-1911.
  • 8Kaneda H, Taguchi J, Ogasawara K, et al.Increased level of advanced oxidation protein products in patients with coronary artery disease.Atherosclerosis,2002,162:221-225.
  • 9Schomin M, EIcnhardt A, Rita E. The micro-inflammatory state of uremia. Blood Purif,2000,18:327-332.
  • 10Santoro A, Mancini E.Cardiac effects of chronic inflammation in dialysis patients.Nephrol Dial Transplant,2002,17 Suppl 8:10-15.

共引文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部